Please login to the form below

Not currently logged in
Email:
Password:

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

Novartis

New phase III data for Novartis’ CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women.

The MONALEESA-7 trial in pre-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer is the first dedicated study to show a benefit for a CDK4/6 blocker in these patients - giving Novartis a boost as it plays catch-up in the market with Pfizer’s first-to-market Ibrance (palbociclib).

In the study, women taking Kisqali (ribociclib) on top of hormonal therapy as a first-line intervention had a longer progression-free survival (PFS) than those on hormonal therapy alone, said Novartis, which is planning to unveil the data at the San Antonio Breast Cancer Symposium (SABCS) in December.

“There remains a significant unmet treatment need in younger women diagnosed with premenopausal advanced breast cancer, as the disease tends to be more aggressive with a poorer prognosis,” commented Samit Hirawat, head of global drug development at Novartis’ oncology unit.

Kisqali was approved earlier this year as a first-line therapy for post-menopausal women with HR-positive, HER2-negative advanced breast cancer based on the results of the MONALEESA-2 study and has been predicted to become a blockbuster for Novartis with sales of $1.2bn, but has a long way to go.

Novartis’ drug made sales of $26m in the third quarter - with a full US launch only taking place in August - while Ibrance brought in $878m for Pfizer, a rise of 60%. Ibrance has been on the market since 2015.

EvaluatePharma thinks Ibrance will become a mega-blockbuster with sales of $6bn-plus in 2022, with Kisqali and other rivals jostling for a distant second place although patients will benefit from greater choice - particularly with regard to toxicity profiles - and potentially lower prices.

Novartis is currently a little ahead of Eli Lilly, whose CDK4/6 inhibitor Verzenio (abemaciclib) was approved in the US, its first market, in September.

Lilly has one leg-up over its rivals, gaining approval as a third-line therapy for women with HR-positive, HER2-negative advanced breast cancer who have received prior hormonal therapy and chemotherapy, which was highlighted by the FDA as a reason for its earlier-than-expected approval.

Article by
Phil Taylor

9th November 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics